Abstract
The antiviral combination drug Mavyret (glecaprevir–pibrentasvir), used to treat patients with hepatitis C virus and compensated cirrhosis, is now approved for a treatment duration of eight weeks in treatment-naive adult and pediatric patients.Changes to the product's labeling regarding the shortened length of therapy are based on preliminary data from the EXPEDITION-8 trial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
